FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
F. Hoffmann-La Roche Ltd Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly…
FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA)…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
Gazyva Data Reshapes Roche Kidney Disease Story As Regulatory Calls Near
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
Roche eyes Gazyva label expansion on positive Phase III kidney disease data
Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…